Skip to main content

Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies

Targeted Oncology volume 14, pages 125–138 (2019)Cite this article

Abstract

Inhibitors of Bruton’s tyrosine kinase (BTK), a major kinase in the B-cell receptor (BCR) signaling pathway, mediating B-cell proliferation and apoptosis, have substantially altered the management, clinical course, and outcome of patients with B-cell malignancies. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Newer and more selective BTK inhibitors are currently in clinical development, including acalabrutinib, which is currently US FDA approved for previously treated mantle cell lymphoma. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control. This review describes the major milestones in the clinical development of BTK inhibitors in chronic lymphocytic leukemia and other B-cell malignancies, highlights the most recent long-term follow-up results, and evaluates the role of BTK inhibitors and their combination with other agents in B-cell malignancies and other indications.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–15.

    Article  CAS  PubMed  Google Scholar 

  2. Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126:1921–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–42.

    Article  CAS  PubMed  Google Scholar 

  5. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–10.

    Article  CAS  PubMed  Google Scholar 

  6. Zenz T, Gribben JG, Hallek M, Doehner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood. 2012;119:4101–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gribben JG. How and when I do allogeneic transplant in CLL. Blood. 2018;132:31–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Davids MS. How should we sequence and combine novel therapies in CLL? ASH Educ Program Book. 2017;2017:346–53.

    Google Scholar 

  9. Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94:193–205.

    Article  CAS  PubMed  Google Scholar 

  10. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17:57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment. Biochem Biophys Acta. 2016;1863:401–13.

    Article  CAS  PubMed  Google Scholar 

  12. Weber ANR, Bittner Z, Liu X, Dang TM, Radsak MP, Brunner C. Bruton’s tyrosine kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ren L, Campbell A, Fang H, Gautam S, Elavazhagan S, Fatehchand K, et al. Analysis of the effects of the Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib on monocyte Fcgamma receptor (FcgammaR) function. J Biol Chem. 2016;291:3043–52.

    Article  CAS  PubMed  Google Scholar 

  15. Ping L, Ding N, Shi Y, Feng L, Li J, Liu Y, et al. The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Oncotarget. 2017;8:39218–29.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30:833–43.

    Article  CAS  PubMed  Google Scholar 

  17. Andersen MA, Eriksen CT, Brieghel C, Biccler JL, Cunha-Bang CD, Helleberg M, et al. Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study. Haematologica. 2018;103(7):e300–3.

    Google Scholar 

  18. U.S. Food and Drug Administration, C.f.D.E.a.R. Imbruvica® (ibrutinib), for oral use: highlights of prescribing information (2018). https://www.imbruvica.com/docs/librariesprovider7/default-document-library/prescribing-information.pdf. Accessed 30 Oct 2018.

  19. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.

    Article  CAS  PubMed  Google Scholar 

  20. Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129:2224–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372:1430–40.

    Article  CAS  PubMed  Google Scholar 

  22. Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18:241–50.

    Article  CAS  PubMed  Google Scholar 

  23. Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2018;36:2755–61.

    Article  CAS  PubMed  Google Scholar 

  24. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl BS, et al. Median 3.5-year follow-up of ibrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: a pooled analysis. Blood. 2017;130:151.

    Google Scholar 

  26. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Stauder R, Eichhorst B, Hamaker ME, Kaplanov K, Morrison VA, Osterborg A, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol. 2017;28:218–27.

    CAS  PubMed  Google Scholar 

  28. O’Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, et al. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131:1910–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16:169–76.

    Article  CAS  PubMed  Google Scholar 

  30. Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131:2357–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–18.

    Article  CAS  PubMed  Google Scholar 

  32. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. O’Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58.

    Article  CAS  PubMed  Google Scholar 

  34. Jones J, Mato A, Coutre S, Byrd JC, Furman RR, Hillmen P, et al. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol. 2018;182:504–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770–8.

    Article  CAS  PubMed  Google Scholar 

  36. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103:1502–10.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, et al. Long-term follow-up of treatment with ibrutinib and rituximab in patients with high-risk chronic lymphocytic leukemia. Clin Cancer Res. 2017;23:2154–8.

    Article  CAS  PubMed  Google Scholar 

  41. Shanafelt TD, Wang V, Kay NE, Hanson CA, O’Brien SM, Barrientos J, et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer Research Group (E1912). Blood. 2018;132:LBA-4.

    Article  CAS  Google Scholar 

  42. Dimopoulos MA, Tedeschi A, Trotman J, Garcia-Sanz R, Macdonald D, Leblond V, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom’s macroglobulinemia. N Engl J Med. 2018;378:2399–410.

    Article  CAS  PubMed  Google Scholar 

  43. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17:48–56.

    Article  CAS  PubMed  Google Scholar 

  44. Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126:842–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2018;20:43–56.

    Article  PubMed  Google Scholar 

  46. Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–11.

    Article  CAS  PubMed  Google Scholar 

  47. Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 2018. https://doi.org/10.1038/s41375-018-0276-9.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Ujjani C, Wang H, Skarbnik A, Trivedi N, Ramzi P, Khan N, Cheson BD. A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. Blood Adv. 2018;2:762–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Jerkeman M, Eskelund CW, Hutchings M, Raty R, Wader KF, Laurell A, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5:e109–16.

    Article  PubMed  Google Scholar 

  50. Jain N, Keating M, Thompson PA, Ferrajoli A, Burger J, Borthakur G, et al. Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk chronic lymphocytic leukemia (CLL). Blood. 2018;132:696.

    Google Scholar 

  51. Hillmen P, Rawstron A, Brock K, Munoz Vincente S, Yates F, Bishop RM, et al. Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the bloodwise TAP Clarity Study. Blood. 2018;132:182.

    Google Scholar 

  52. Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378:1211–23.

    Article  CAS  PubMed  Google Scholar 

  53. Rogers KA, Huang Y, Ruppert AS, Awan FT, Heerema NA, Hoffman C, et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood. 2018;132:1568–72.

    Article  CAS  PubMed  Google Scholar 

  54. Rogers KA, Huang Y, Ruppert AS, Awan F, Hoffman C, Maddocks K, et al. Phase 2 study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. Blood. 2018;132:693.

    Google Scholar 

  55. Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2019;6:e38–47.

    Article  PubMed  Google Scholar 

  56. Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, et al. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019;6:e100–9.

    Article  PubMed  Google Scholar 

  57. Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127:1117–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Herman SE, Mustafa RZ, Jones J, Wong DH, Farooqui M, Wiestner A. Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo. Clin Cancer Res. 2015;21:4642–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, et al. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014;123:4132–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight. 2017;2:e89904.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Brown JR, Moslehi J, O’Brien S, Ghia P, Hillmen P, Cymbalista F, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796–805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1:1739–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Reda G, Fattizzo B, Cassin R, Mattiello V, Tonella T, Giannarelli D, et al. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study. J Hematol Oncol. 2018;11:79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Guha A, Derbala MH, Zhao Q, Wiczer TE, Woyach JA, Byrd JC, et al. Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies. J Am Coll Cardiol. 2018;72:697–8.

    Article  PubMed  Google Scholar 

  66. Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100:1571–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017;1:772–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Kazianka L, Drucker C, Skrabs C, Thomas W, Melchardt T, Struve S, et al. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia. 2017;31:1117–22.

    Article  CAS  PubMed  Google Scholar 

  70. Varughese T, Taur Y, Cohen N, Palomba ML, Seo SK, Hohl TM, Redelman-Sidi G. Serious infections in patients receiving ibrutinib for treatment of lymphoid malignancies. Clin Infect Dis. 2018;67:687–92.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  71. Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131:1955–9.

    Article  CAS  PubMed  Google Scholar 

  72. Bercusson A, Colley T, Shah A, Warris A, Armstrong-James D. Ibrutinib blocks Btk-dependent NF-kB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018;132:1985–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Rogers KA, Luay M, Zhao Q, Wiczer T, Levine L, Zeinab EB, et al. Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center. Blood. 2017;130:830.

    Google Scholar 

  74. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80–7.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SE, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126:2213–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. O’Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, et al. Prognostic factors for complete response to ibrutinib in patients with chronic lymphocytic leukemia: a pooled analysis of 2 clinical trials. JAMA Oncol. 2018;4:712–6.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Thompson PA, O’Brien SM, Xiao L, Wang X, Burger JA, Jain N, et al. beta2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 2016;122:565–73.

    Article  CAS  PubMed  Google Scholar 

  78. Barr PM, Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129:2612–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Thompson PA, O’Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121:3612–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, et al. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv. 2017;1:1584–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Woyach JA, Furman RR, Liu T-M, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, et al. Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015;126:61–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129:1469–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35:1437–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Landau DA, Sun C, Rosebrock D, Herman SE, Fein J, Sivina M, et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017;8:2185.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8:364ra155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Dubois S, Viailly PJ, Mareschal S, Bohers E, Bertrand P, Ruminy P, et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res. 2016;22:2919–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, et al. Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia. Blood. 2017;129:2519–25.

    Article  CAS  PubMed  Google Scholar 

  90. Paulus A, Akhtar S, Yousaf H, Manna A, Paulus SM, Bashir Y, et al. Waldenstrom macroglobulinemia cells devoid of BTK (C481S) or CXCR4 (WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017;7:e565.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Lampson BL, Brown JR. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol. 2018;11:185–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26:1175–9.

    Article  CAS  PubMed  Google Scholar 

  94. Woyach JA. How I manage ibrutinib-refractory chronic lymphocytic leukemia. Blood. 2017;129:1270–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Ding W. Richter transformation in the era of novel agents. Hematology. 2018;2018:256–63.

    PubMed  Article  Google Scholar 

  96. Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65–75.

    Article  CAS  PubMed  Google Scholar 

  97. Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28:1050–6.

    Article  CAS  PubMed  Google Scholar 

  98. Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified t cells after failure of ibrutinib. J Clin Oncol. 2017;35:3010–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Robinson HR, Qi J, Cook EM, Nichols C, Dadashian EL, Underbayev C, et al. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. Blood. 2018;132:521–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129:3419–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659–67.

    Article  CAS  PubMed  Google Scholar 

  103. U.S. Food and Drug Administration, C.f.D.E.a.R. CALQUENCE® (alabrutinib) capsules, for oral use: highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf. Accessed 30 Oct 2018.

  104. Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, et al. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018;32:920–30.

    Article  CAS  PubMed  Google Scholar 

  105. Niemann CU, Mora-Jensen HI, Dadashian EL, Krantz F, Covey T, Chen SS, et al. Combined BTK and PI3Kdelta inhibition with acalabrutinib and ACP-319 improves survival and tumor control in CLL mouse model. Clin Cancer Res. 2017;23:5814–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127:411–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, et al. Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059. Blood. 2017;129:2808–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Tam C, Grigg AP, Opat S, Ku M, Gilbertson M, Anderson MA, et al. The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood. 2015;126:832.

  109. Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, et al. Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2016;101:e295–8.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Cramer P, von Tresckow J, Bahlo J, Engelke A, Langerbeins P, Fink AM, et al. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018;14:499–513.

    Article  CAS  PubMed  Google Scholar 

  111. Woyach JA. What is the optimal management of older CLL patients? Best Pract Res Clin Haematol. 2018;31:83–9.

    Article  PubMed  Google Scholar 

  112. Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv. 2018;2:2012–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Ryan CE, Sahaf B, Logan AC, O’Brien S, Byrd JC, Hillmen P, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016;128:2899–908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7:1018–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study. J Clin Oncol. 2018;36:2405–12.

    Article  CAS  PubMed  Google Scholar 

  116. Campbell R, Chong G, Hawkes EA. Novel indications for Bruton’s tyrosine kinase inhibitors, beyond hematological malignancies. J Clin Med. 2018;7:E62.

    Article  PubMed  CAS  Google Scholar 

  117. Maharaj K, Sahakian E, Pinilla-Ibarz J. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia. Blood Adv. 2017;1:1867–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Investig. 2017;127:3052–64.

    Article  PubMed  Google Scholar 

  119. Niemann CU, Herman SE, Maric I, Gomez-Rodriguez J, Biancotto A, Chang BY, et al. Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib-findings from an investigator-initiated phase II study. Clin Cancer Res. 2016;22:1572–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Division of Hematology, Department of Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, 455D Wiseman Hall, 410 W 12th Ave, Columbus, OH, 43210, USA

    Fabienne Lucas & Jennifer A. Woyach

  2. Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA

    Jennifer A. Woyach

Authors
  1. Fabienne Lucas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer A. Woyach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer A. Woyach.

Ethics declarations

Funding

No sources of funding were used to prepare this manuscript.

Conflict of interest

Fabienne Lucas has no conflicts of interest that might be relevant to the contents of this manuscript. Jennifer A. Woyach receives research funding from Abbvie, Janssen, Acerta, Pharmacyclics, Loxo, Karyopharm, Morphosys and has consulted for Janssen and Pharmacyclics.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lucas, F., Woyach, J.A. Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies. Targ Oncol 14, 125–138 (2019). https://doi.org/10.1007/s11523-019-00635-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-019-00635-7